Cargando…

Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis

BACKGROUND: Liposomal formulations of anthracyclines appear to have favorable toxicity profile when compared with conventional anthracyclines in elderly, high risk cardiac patients and patients with prior use of anthracyclines. Randomized controlled trials have evaluated the efficacy and safety prof...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rafiyath, Shamudheen M, Rasul, Mohammad, Lee, Byung, Wei, Guoqing, Lamba, Gurpreet, Liu, Delong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3514106/ https://www.ncbi.nlm.nih.gov/pubmed/23210520 http://dx.doi.org/10.1186/2162-3619-1-10

Ejemplares similares

Recent advances and novel agents for gastrointestinal stromal tumor (GIST)
por: Lamba, Gurpreet, et al.
Publicado: (2012)

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
por: Wei, Guoqing, et al.
Publicado: (2010)

Cardiac Safety of Pegylated Liposomal Doxorubicin After Conventional Doxorubicin Exposure in Patients With Sarcoma and Breast Cancer
por: Alhaja, Maher, et al.
Publicado: (2023)

The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial
por: Al-Batran, S-E, et al.
Publicado: (2006)

Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer
por: Schettini, Francesco, et al.
Publicado: (2021)

Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system
por: Fukuda, Akiho, et al.
Publicado: (2017)

Pegylated liposomal doxorubicin (PLD): enhanced skin toxicity in areas of vitiligo
por: Yuan, Y, et al.
Publicado: (2008)

Radiotherapy and anthracyclines – cardiovascular toxicity
por: Mozdzanowska, Dagmara, et al.
Publicado: (2014)

Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer: The APPROVE Randomized Clinical Trial
por: Wang, Tiantian, et al.
Publicado: (2022)

Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation
por: Rahman, Atiar M, et al.
Publicado: (2007)

Doxorubicin and Aclarubicin: Shuffling Anthracycline Glycans for Improved Anticancer Agents
por: Wander, Dennis P. A., et al.
Publicado: (2020)

The cost implications of the use of pegylated liposomal doxorubicin when choosing an anthracycline for the treatment of platinum-resistant ovarian cancer: A low-value intervention?
por: Cohn, David E., et al.
Publicado: (2015)

Safety and efficacy of pegylated liposomal doxorubicin in HIV-associated Kaposi’s sarcoma
por: Cainelli, Francesca, et al.
Publicado: (2009)

Current management and prognostic features for gastrointestinal stromal tumor (GIST)
por: Lamba, Gurpreet, et al.
Publicado: (2012)

Anthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials
por: Al-Batran, S-E, et al.
Publicado: (2010)

Pegylated liposomal doxorubicin in ovarian cancer
por: Green, Andrew E, et al.
Publicado: (2006)

Pegylated liposomal doxorubicin in ovarian cancer
por: Strother, Robert, et al.
Publicado: (2009)

Pegylated liposomal doxorubicin for myeloid neoplasms
por: Zhang, Cheng, et al.
Publicado: (2019)

Comparison of Conventional Chemotherapy, Stealth Liposomes and Temperature-Sensitive Liposomes in a Mathematical Model
por: Gasselhuber, Astrid, et al.
Publicado: (2012)

Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma
por: Golfieri, R, et al.
Publicado: (2014)

Liposomal co-delivered oleanolic acid attenuates doxorubicin-induced multi-organ toxicity in hepatocellular carcinoma
por: Sarfraz, Muhammad, et al.
Publicado: (2017)

Extracorporeal Removal of Thermosensitive Liposomal Doxorubicin from Systemic Circulation after Tumor Delivery to Reduce Toxicities
por: Motamarry, Anjan, et al.
Publicado: (2022)

Maleimide-Functionalized Liposomes: Prolonged Retention and Enhanced Efficacy of Doxorubicin in Breast Cancer with Low Systemic Toxicity
por: Tang, Chuane, et al.
Publicado: (2022)

Efficacy and toxicity of CLAG combined with pegylated liposomal doxorubicin in the treatment of refractory or relapsed acute myeloid leukemia
por: Yao, Han, et al.
Publicado: (2023)

Comparative effects of free doxorubicin, liposome encapsulated doxorubicin and liposome co-encapsulated alendronate and doxorubicin (PLAD) on the tumor immunologic milieu in a mouse fibrosarcoma model
por: Islam, Md. Rakibul, et al.
Publicado: (2022)

Pegylated liposomal doxorubicin (Duomeisu(®)) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study
por: Jiang, Hanfang, et al.
Publicado: (2023)

Pegylated liposomal doxorubicin in the management of ovarian cancer
por: Ferrandina, Gabriella, et al.
Publicado: (2010)

A tale of the two PEGylated liposomal doxorubicins
por: Chou, Hunghsueh, et al.
Publicado: (2015)

Liposomal doxorubicin-induced palmoplantar erythrodysthesia syndrome
por: Yadav, Nidhi, et al.
Publicado: (2015)

Analytical ultracentrifugation for analysis of doxorubicin loaded liposomes
por: Mehn, Dora, et al.
Publicado: (2017)

Pharmacokinetics of a liposomal formulation of doxorubicin in rats
por: Liu, Zongyu, et al.
Publicado: (2017)

Recent Preclinical and Clinical Progress in Liposomal Doxorubicin
por: Aloss, Kenan, et al.
Publicado: (2023)

Immunotoxicity of multiple dosing regimens of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes.
por: Rahman, A., et al.
Publicado: (1986)

Anthracycline-induced toxicity affecting palmar and plantar skin.
por: Jones, A. P., et al.
Publicado: (1989)

Comparative Cardiac Toxicity of Anthracyclines In Vitro and In Vivo in the Mouse
por: Toldo, Stefano, et al.
Publicado: (2013)

Cardiac Toxicity and Anthracyclines: Mechanism, Interventions, and the Trouble With Troponin
por: Thompson, Grace E., et al.
Publicado: (2019)

Toxicity, outcome, and management of anthracycline overdoses in 16 dogs
por: Lawson, Haylie C., et al.
Publicado: (2021)

ROS-responsive liposomes with NIR light-triggered doxorubicin release for combinatorial therapy of breast cancer
por: Yi, Hanxi, et al.
Publicado: (2021)

Preclinical safety and efficacy studies with an affinity-enhanced epithelial junction opener and PEGylated liposomal doxorubicin
por: Richter, Maximilian, et al.
Publicado: (2015)

Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer
por: Jones, Robin L., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tqrrdc5t21okiqc7u278b7okjp